Complement activation by PEGylated liposomes containing prednisolone

Alving, 1977, Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes, J. Immunol., 118, 342, 10.4049/jimmunol.118.1.342

Amselem, 1993, A large-scale method for the preparation of sterile and non-pyrogenic liposomal formulations of defined size distributions for clinical use, 501

Bates, 1995, Anaphylaxis due to liposomal amphotericin (AmBisome), Genitourin. Med., 71, 414

Bradley, 1998, Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids, Arch. Biochem. Biophys., 357, 185, 10.1006/abbi.1998.0798

Buyon, 1992, Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement, Arthritis Rheum., 35, 1028, 10.1002/art.1780350907

Chanan-Khan, 2003, Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions, Ann. Oncol., 14, 1430, 10.1093/annonc/mdg374

Duncan, 2005, Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer, Endocr. Relat. Cancer, 12, S189, 10.1677/erc.1.01045

Hamad, 2010, Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering, ACS Nano, 4, 6629, 10.1021/nn101990a

Kirschfink, 2003, Modern complement analysis, Clin. Vaccine Immunol, 10, 982, 10.1128/CDLI.10.6.982-989.2003

Knop, 2010, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives, Angew. Chem. Int. Ed., 49, 6288, 10.1002/anie.200902672

Laing, 1994, Anaphylactic reactions to liposomal amphotericin, Lancet, 344, 682, 10.1016/S0140-6736(94)92116-4

Maeda, 2000, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control Release, 65, 271, 10.1016/S0168-3659(99)00248-5

Metselaar, 2002, Liposomes for intravenous drug targeting: design and applications, Mini Rev. Med. Chem., 2, 319, 10.2174/1389557023405873

Moghimi, 2010, Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead, J. Control Release, 146, 175, 10.1016/j.jconrel.2010.04.003

Moghimi, 2010, Complement monitoring of carbon nanotubes, Nat. Nano, 5, 382, 10.1038/nnano.2010.109

Moghimi, 2011, Material properties in complement activation, Adv. Drug Deliv. Rev., 63, 1000, 10.1016/j.addr.2011.06.002

Moghimi, 2006, Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production, FASEB J., 20, 2591, 10.1096/fj.06-6186fje

Müller-Eberhard, 1984, The membrane attack complex, Springer Semin. Immunopathol., 7, 93, 10.1007/BF01893017

Reddy, 2000, Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs, Ann. Pharmacother., 34, 915, 10.1345/aph.10054

Romberg, B., 2007. Poly(amino acid)s: Next-generation Coatings for Long-Circulating Liposomes [PhD thesis], Utrecht University, Utrecht, The Netherlands, pp. 90–99.

Romberg, 2007, Poly(amino acid)s: promising enzymatically degradable stealth coatings for liposomes, Int. J. Pharm., 331, 186, 10.1016/j.ijpharm.2006.11.018

Schneider, 1998, Anaphylactic reaction to liposomal amphotericin (AmBisome), Br. J. Haematol., 102, 1108, 10.1046/j.1365-2141.1998.0952a.x

Swartz, 1988, Antibodies to cholesterol, Proc. Natl. Acad. Sci. USA, 85, 1902, 10.1073/pnas.85.6.1902

Szebeni, 2012, Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions, Eur. J. Nanomed., 4, 33, 10.1515/ejnm-2012-0002

Szebeni, 2002, Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies, J. Liposome Res., 12, 165, 10.1081/LPR-120004790

Szebeni, 2005, Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity, Toxicology, 216, 106, 10.1016/j.tox.2005.07.023

Szebeni, 2000, Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction, Am. J. Physiol. Heart Circ. Physiol., 279, H1319, 10.1152/ajpheart.2000.279.3.H1319

Szebeni, 2003, The interaction of liposomes with the complement system: in vitro and in vivo assays, Methods Enzymol., 373, 136, 10.1016/S0076-6879(03)73010-9

Szebeni, 2012, Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and Am Bisome, Nanomedicine, 8, 176, 10.1016/j.nano.2011.06.003

Szebeni, 2011, Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention, Adv. Drug Deliv. Rev., 63, 1020, 10.1016/j.addr.2011.06.017

Vaidya, 2002, Anaphylactic reaction to liposomal amphotericin B, Ann. Pharmacother., 36, 1480, 10.1345/aph.1C001

Wassef, 1989, Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs, J. Immunol., 143, 2990, 10.4049/jimmunol.143.9.2990